Striking the right balance with type I interferon signalling in cancer - PubMed
5 hours ago
- #Type I Interferons
- #Tumour Microenvironment
- #Cancer Therapy
- Type I interferons (IFNs), such as IFNα and IFNβ, play a crucial role in cancer therapy by enhancing antitumour immunity and improving treatment efficacy.
- Clinical success of IFN-based treatments in solid malignancies has been limited due to toxicity and variable therapeutic outcomes.
- Type I IFNs exhibit both immune-stimulatory and immune-suppressive effects in tumours, influenced by oncogenic signalling, chromatin state, and the tumour microenvironment.
- The review explores tumour-intrinsic mechanisms controlling canonical and chronic IFN signalling and their impact on immune surveillance, metastasis, and therapy response.
- Age-related changes, including immunosenescence and stromal alterations, modulate type I IFN signalling and affect therapeutic outcomes.
- The review outlines actionable strategies to reprogramme IFN activity in tumours to enhance therapy response.